Anti-microbial soluble hemostatic gauze and method of making same
OwnerGao Jing Xing, Hong Zhang Xuinventors
Life of this patent
Estimating the term…
Abstract
A soluble hemostatic gauze is made from a cotton gauze immersed in an aqueous solution of from 90% to 95% ethanol at room temperature for at least 50 minutes and then exposed to an aqueous solution of NaOH at a temperature of from 35° to 40° C. for from 90 to 150 minutes. Next the cotton gauze is kept in an aqueous solution of acetic chloride at a temperature of from 35° to 40° C. for from 90 to 150 minutes and then washed in an aqueous solution of ethanol for a sufficient time to neutralize the cotton gauze and remove residue salts from the gauze resulting in a soluble hemostatic gauze. That soluble hemostatic gauze is then dried. An antibiotic or other pharmaceutically effective agent may be linked to the gauze molecules.
Claims22
A hemostatic gauze material comprising soluble cellulose molecules each having a carboxyl group and a pharmaceutically effective agent of the type containing an amino-group, the amino group attached to the carboxyl group of the cellulose molecules.
A method of making a soluble hemostatic gauze comprising:
- a. providing a cotton gauze;
- b. immersing the cotton gauze in a solution of from 90% to 95% ethanol, methanol or acetone at room temperature;
- c. exposing the cotton gauze to a solution of from 10% to 70% alkaline material at a temperature of from 20° C. to 50° C. for from 1 to 4 hours;
- d. exposing the cotton gauze to a solution of from 20% to 80% of an acid or acid salt having a COOH group at a temperature of from 20° C. to 80° C. for from 1 to 6 hours to attach COOH groups to molecules in the cotton gauze;
- e. washing the cotton gauze in ethanol, methanol or acetone at a temperature of from 10° C. to 60° C. for a sufficient time to neutralize the cotton gauze and remove residue salts from the gauze resulting in a solible hemostatic gauze;
- and
- f. drying the soluble hemostatic gauze.
The method of claim 16 wherein the chemotherapy agent is selected form the group consisting of paclitaxel, bleomycin, mitomycine, gemcitabine, and fluorouracil.
Dependencies are inferred from the claim text.